The company reported strong growth for Kedrab and Cytogam products, with an estimated market share of 40-50%. InnovAte trial enrollment is at 50%, with ongoing discussions with the FDA.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Increased EBITDA ...
